FST and carcinoma: The lack of the significant correlation between follistatin and AMH levels is supported by an experimental study conducted by Kawagishi et al. [36] on an embryonic carcinoma cell line, which demonstrated that the maximum bioactivity of recombinant human AMH was not altered by follistatin.